Spinal Muscular Atrophy Type 3 (Kugelberg-Welander): Ambulatory Preservation in the Nusinersen Era
In short
SMA Type 3 physiotherapy maximizes independent ambulation through targeted HFMSE motor testing, fatigue management, and synergistic disease-modifying therapies.
In this guide (4 sections)
SMN1 Loss, SMN2 Modifier Biology, and Juvenile Anterior Horn Survival
Spinal Muscular Atrophy Type 3 (SMA 3), historically known as Kugelberg-Welander disease, is an autosomal recessive motor neuron disease caused by homozygous deletions or loss-of-function mutations in the SMN1 gene on chromosome 5q13. Survival of motor neurons in SMA 3 is mediated by the presence of 3 to 4 copies of the centromeric paralog gene SMN2. SMN2 differs from SMN1 by a single critical C-to-T transition in exon 7, causing alternative splicing where 85% to 90% of transcribed transcripts lack exon 7 (SMN-delta-7), yielding a truncated, unstable, rapidly degraded protein.
The remaining 10% to 15% of full-length functional SMN protein generated by multiple SMN2 copies is sufficient to support normal embryonic motor development and early infancy. Consequently, children with SMA Type 3 achieve the milestone of unassisted independent walking before developing progressive lower motor neuron weakness. Onset occurs after 18 months of age: SMA 3a manifests before age 3, whereas SMA 3b develops between age 3 and 20 years. Progressive anterior horn cell degeneration results in proximal lower limb weakness, a waddling gluteal gait, Gowers' sign, hand tremors, and gradual loss of unassisted ambulation.
Standardized Clinical Outcome Measures in the Disease-Modifying Era
| Clinical Assessment Tool | Target Motor Domain | Standard Scoring System | Treatment Response & Drug Efficacy Marker | |
|---|---|---|---|---|
| Expanded HFMSE (Hammersmith) | 33 functional motor items (rolling, sitting, standing, squatting, hopping) | Scored 0 to 66 points (2 points per completed task) | A 3+ point improvement indicates clinically meaningful therapeutic response | |
| 6-Minute Walk Test (6MWT) | Distance walked continuously in 6 minutes down a 30-meter corridor | Normal distance in healthy adolescents is 550 to 650 meters | Measures pathological fatigue: walking speed drops sharply from minute 1 to minute 6 | |
| Revised Upper Limb Module (RULM) | 19 upper extremity functional reaching, lifting, and grasping items | Scored 0 to 37 points | Captures manual dexterity and tabletop arm function in non-ambulatory SMA 3 | |
| Vignos Functional Mobility Scale | 10-grade lower extremity mobility classification | Grade 1 (climbs stairs without rails) to Grade 10 (confined to bed) | Tracks long-term preservation of functional community walking | |
| Hand-Held Dynamometry (HHD) | Quantitative isometric strength of quadriceps, hamstrings, and deltoids | Measured in Newtons (N) of force output | Detects subclinical strength gains before gross motor scale improvements |
Standardized Clinical Rehabilitation Protocols in the Era of SMN Therapeutics
- Synergistic Exercise with Disease-Modifying Therapies (Nusinersen / Risdiplam): Coordinate therapy closely with anti-sense oligonucleotide or small-molecule SMN2 splice-modifying drugs; increasing SMN protein rescues dying motor neurons, creating a biological window where active resistive exercise and motor skill retraining can build functional muscle mass.
- Management of Pathological Neuromuscular Fatigue: Incorporate interval rest breaks during physical activity; fatigue curves on the 6-Minute Walk Test demonstrate that motor neuron transmission failure accelerates under continuous exertion; pacing prevents neuromuscular junction conduction blocks.
- Dynamic Ground-Reaction Ankle-Foot Orthoses (GRAFOs): Fit custom carbon-fiber ground-reaction AFOs; quadriceps weakness causes the knee to buckle into flexion during stance phase; the rigid anterior tibial shell of a GRAFO generates a passive knee extension moment, stabilizing the knee without exhausting the quadriceps.
Frequently Asked Questions
Can a child with SMA Type 3 walk independently?
Yes. By definition, all children with SMA Type 3 learn to walk independently as toddlers. While muscle weakness can cause them to lose walking ability during adolescence or adulthood if untreated, modern breakthrough medications and dedicated physiotherapy are now keeping many patients walking throughout their lives.
How do modern medicines like Spinraza (Nusinersen) change physiotherapy for SMA?
In the past, physiotherapy for SMA focused solely on comfort and slowing decline. Today, breakthrough medications stimulate the body to produce healthy SMN protein, which rescues motor nerves. Physiotherapy now works like an active gym program to strengthen muscles that were once thought permanently lost.
Why does a person with SMA Type 3 walk fast at first and then suddenly slow down?
This is called neuromuscular fatigue. Because they have fewer working motor nerves, their remaining nerve endings have to fire at top speed to keep them moving. After 2 or 3 minutes of walking, the nerves run low on chemical messengers, causing the legs to suddenly feel heavy and sluggish.
Related condition guides
Related recovery guides & articles
BookPhysio.in Editorial Team
The BookPhysio.in editorial team writes and maintains this content, checking it against reliable clinical sources. Content follows our medical review policy: general information only, and no page claims a clinical review until a named registered physiotherapist has signed it off.
Read our medical review policy